{"title":"不寻常的沙利放线菌（原名沙利放线菌）菌血症。","authors":"Lu-Qing Zheng, Qing-Yong Wang","doi":"10.7754/Clin.Lab.2024.241238","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This study aimed to evaluate unusual case reports about Actinotigum schaalii (A. schaalii) bacteremia patients in the past 20 years.</p><p><strong>Methods: </strong>A retrospective review of A. schaalii bacteremia patients collected from MEDLINE between January 2005 and November 2024.</p><p><strong>Results: </strong>Of 34 cases, the identification (ID) of A. schaalii for clinical samples included blood (n = 34), urine (n = 6), valve (n = 1), and biopsy (n = 1). Polymicrobial infections were 32.4% (n = 11 out of 34) in this study. Antimicrobial susceptibility tests (ASTs) were performed in most cases. The A. schaalii isolates were sensitive to penicillin, β-lactam combination agent, lincosamide, tetracycline, nitrofuran, cephem, carbapenem, oxazolidinone, ansamycin, macrolide, and glycylcycline; but resistant to fluoroquinolone, nitroimidazole, aminoglycoside, and folate pathway antagonists.</p><p><strong>Conclusions: </strong>Microbiologists should perform the correct ID and suitable AST of the potentially invasive A. schaalii to help clinicians obtain the appropriate antimicrobial coverage for serious systemic infections.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 6","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Unusual Actinotigum schaalii (Formerly Named Actinobaculum schaalii) Bacteremia.\",\"authors\":\"Lu-Qing Zheng, Qing-Yong Wang\",\"doi\":\"10.7754/Clin.Lab.2024.241238\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>This study aimed to evaluate unusual case reports about Actinotigum schaalii (A. schaalii) bacteremia patients in the past 20 years.</p><p><strong>Methods: </strong>A retrospective review of A. schaalii bacteremia patients collected from MEDLINE between January 2005 and November 2024.</p><p><strong>Results: </strong>Of 34 cases, the identification (ID) of A. schaalii for clinical samples included blood (n = 34), urine (n = 6), valve (n = 1), and biopsy (n = 1). Polymicrobial infections were 32.4% (n = 11 out of 34) in this study. Antimicrobial susceptibility tests (ASTs) were performed in most cases. The A. schaalii isolates were sensitive to penicillin, β-lactam combination agent, lincosamide, tetracycline, nitrofuran, cephem, carbapenem, oxazolidinone, ansamycin, macrolide, and glycylcycline; but resistant to fluoroquinolone, nitroimidazole, aminoglycoside, and folate pathway antagonists.</p><p><strong>Conclusions: </strong>Microbiologists should perform the correct ID and suitable AST of the potentially invasive A. schaalii to help clinicians obtain the appropriate antimicrobial coverage for serious systemic infections.</p>\",\"PeriodicalId\":10384,\"journal\":{\"name\":\"Clinical laboratory\",\"volume\":\"71 6\",\"pages\":\"\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical laboratory\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.7754/Clin.Lab.2024.241238\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical laboratory","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7754/Clin.Lab.2024.241238","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
The Unusual Actinotigum schaalii (Formerly Named Actinobaculum schaalii) Bacteremia.
Background: This study aimed to evaluate unusual case reports about Actinotigum schaalii (A. schaalii) bacteremia patients in the past 20 years.
Methods: A retrospective review of A. schaalii bacteremia patients collected from MEDLINE between January 2005 and November 2024.
Results: Of 34 cases, the identification (ID) of A. schaalii for clinical samples included blood (n = 34), urine (n = 6), valve (n = 1), and biopsy (n = 1). Polymicrobial infections were 32.4% (n = 11 out of 34) in this study. Antimicrobial susceptibility tests (ASTs) were performed in most cases. The A. schaalii isolates were sensitive to penicillin, β-lactam combination agent, lincosamide, tetracycline, nitrofuran, cephem, carbapenem, oxazolidinone, ansamycin, macrolide, and glycylcycline; but resistant to fluoroquinolone, nitroimidazole, aminoglycoside, and folate pathway antagonists.
Conclusions: Microbiologists should perform the correct ID and suitable AST of the potentially invasive A. schaalii to help clinicians obtain the appropriate antimicrobial coverage for serious systemic infections.
期刊介绍：
Clinical Laboratory is an international fully peer-reviewed journal covering all aspects of laboratory medicine and transfusion medicine. In addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies. The journal publishes original articles, review articles, posters, short reports, case studies and letters to the editor dealing with 1) the scientific background, implementation and diagnostic significance of laboratory methods employed in hospitals, blood banks and physicians'' offices and with 2) scientific, administrative and clinical aspects of transfusion medicine and 3) in addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
